AR and prostate carcinoma: Our data suggest that elevated levels of CCM1 can potentiate both ligand-dependent and ligand-independent AR signaling in the TME through the upregulation of YAP/TAZ signaling and that the resultant increase in AR signaling may also be important for progression to advanced prostate cancer.